GO2 for Lung Cancer first secured a congressional appropriation of $20M in 2008 for fiscal year 2009 to fund the Lung Cancer Research Program (LCRP) for innovative lung cancer research. The LCRP is within the Congressionally Directed Medical Research Programs (CDMRP) administered by the Department of Defense.

LCRP VISION
To eradicate deaths and suffering from lung cancer to better the health and welfare of service members, veterans, and the general public.¹

LCRP MILITARY RELEVANCE
The LCRP supports research that is relevant to the healthcare needs of military service members, veterans, and their families.

• 900,000 veterans remain at risk for lung cancer due to age, smoking, and other environmental exposures during and after military service.

• More than 26,000 people have outpatient treatments or hospitalizations within the Military Health System (MHS) due to lung cancer per year.

• There are over 45,000 bed days and more than 270,000 outpatient encounters for lung cancer per year within the MHS.

FUNDING HISTORY
Over its 14-year history, the LCRP funding has fluctuated from year to year, affecting its ability to fund only 30% of research proposals rated excellent or outstanding by reviewers. This bar graph shows the program’s funding from 2009 to 2023, totaling $220.5M since its inception.²

Congress must answer the call to action for lung cancer, the leading cause of cancer deaths in the U.S.
FUND LCRP at $60M in FY2025

¹ Source: https://cdmrp.army.mil/lcrp/
² Source: https://cdmrp.army.mil/lcrp/